Kura’s Leukemia Drug Sales Grow as Partnership and Financing Shape Future Returns

Kura Oncology’s first commercial medicine is gaining traction in a narrowly defined group of leukemia patients. KOMZIFTI generated $13.9 million in U.S. net product revenue in the third quarter of 2026, up 53% from $9.1 million in the second quarter. Kura reported approximately 150 new patient starts, up 30% sequentially, and more than 420 prescriptions including refills.

The figures show progress in the launch, but they do not translate directly into profit attributable to Kura. The company shares U.S. commercialization profits and losses with its partner Kyowa Kirin, while continuing to fund clinical development. A new financing adds capital for that work and a future claim on U.S. sales. The larger commercial opportunity depends on whether the medicine can move into treatment of newly diagnosed patients, with initial Phase 3 results expected in 2028.

A targeted treatment in a competitive market

Acute myeloid leukemia, or AML, is a cancer of the blood and bone marrow that can progress rapidly. KOMZIFTI, the brand name for ziftomenib, is a once-daily oral medicine that inhibits menin, a protein involved in processes that help certain leukemia cells maintain their malignant state.

The FDA approved KOMZIFTI in November 2025 for adults whose AML has a susceptible NPM1 mutation, has returned or not responded to treatment, and has no satisfactory alternative options. That population is narrower than all patients with AML or even all patients with the mutation. Testing, prior treatment and clinical suitability determine who falls within the approved use.

Approval was based on a single-arm study of 112 adults. The combined rate of complete remission or complete remission with partial blood-count recovery was 21.4%, and the median duration of those responses was five months. The study had no randomized comparator. The label warns of differentiation syndrome, a potentially fatal inflammatory reaction, as well as heart-rhythm effects; monitoring and management are part of treatment.

Kura is not alone in this market. The FDA also approved Syndax Pharmaceuticals’ REVUFORJ for relapsed or refractory NPM1-mutated AML in eligible adults and children. The available separate studies do not establish comparative efficacy between the drugs. Kura says KOMZIFTI held a majority of new patient starts within the menin-inhibitor class for the relevant relapsed or refractory NPM1-mutated market, a management-reported measure of new starts rather than all treated AML patients.

The launch is growing, with costs still to absorb

Kura’s third-quarter results combine product sales with revenue recognized under its collaboration. The two have different economic drivers.

Product revenue increased from $9.122 million in the preceding quarter to $13.922 million, a 52.6% rise before rounding. New patient starts and prescriptions also increased, although prescriptions include refills and are not the same as individual patients. Expanding the number of prescribing accounts and generating repeat prescriptions are Kura’s stated commercial priorities.

Third-quarter cost of product sales was just $0.4 million, equivalent to about 2.7% of product revenue. That is not a reliable steady-state manufacturing margin: the quarterly filing says inventory manufactured before approval had already been expensed through research and development. Kura expects product costs to rise relative to sales as that inventory is depleted. The $13.6 million difference between product revenue and product costs also excludes selling expenses, development spending and the economics shared with Kyowa Kirin.

Research and development expense was $66.9 million in the quarter, and selling, general and administrative expense was $30.2 million. Together with product costs, these produced a $74.7 million operating loss; $4.4 million of net other income reduced the net loss to $70.2 million. The prior-year net loss was $74.1 million. Kura’s filing describes a $30.6 million gain on deconsolidation and an equal loss on an equity-method investment, which offset in net other income.

What Kura retains from the partnership

Under its agreement with Kyowa Kirin, Kura leads U.S. development, manufacturing and commercialization and records U.S. product revenue. The companies share U.S. commercialization profits or losses equally. Kyowa Kirin holds exclusive rights outside the United States for the covered hematologic malignancies. The profit-sharing arrangement makes product sales an incomplete measure of the earnings ultimately attributable to Kura.

Collaboration revenue is separate from product revenue and reflects accounting recognition for services and other obligations under the agreement. Kura updated its 2026 collaboration-revenue forecast to $40 million to $45 million. Having recognized $33.168 million in the first nine months, it implies approximately $6.8 million to $11.8 million in the fourth quarter. Management says the guidance reflects noncash accounting recognition as obligations are fulfilled, not the timing of cash receipts.

That difference is visible in the balance sheet. At September 30, Kura reported $275.3 million of contract liabilities associated with consideration already received for commercialization and profit-and-loss or expense sharing. Recognition of those amounts over time does not create a second cash payment from Kyowa Kirin.

Cash runway and the new financing

Kura held $492.1 million in cash, cash equivalents and short-term investments at September 30, down from $667.2 million at the end of 2025. The company used $202.8 million in operating activities in the first nine months, compared with $181.3 million a year earlier.

The 2026 operating cash outflow began with a $211.9 million net loss. Noncash stock compensation added back $24.8 million, while a $30.0 million reduction in contract liabilities used cash in the reconciliation; changes in receivables, inventory and other operating accounts also affected the total. Kura raised approximately $31.5 million net through the sale of 2.56 million shares during the third quarter. The proceeds helped support liquidity, but the financing activity does not change the operating cash outflow.

On November 9, after the balance-sheet date, Kura closed an Oberland Capital financing described as providing up to $300 million across debt and equity. It received $50 million of debt before fees and $5 million from an equity investment at closing. Part of the loan proceeds repaid the $10 million outstanding principal under its previous Hercules loan, plus accrued interest and legal fees. The $55 million headline therefore exceeds the net incremental cash from the transaction.

The remaining funding is conditional. Up to $225 million of additional debt includes $75 million in two company-option tranches subject to conditions, a $50 million tranche tied to positive Phase 3 data and up to $100 million subject to mutual agreement. The data-linked tranche is mandatory once available unless the second tranche has already been funded. A further $20 million of potential equity comprises a $5 million purchase tied to that tranche and an investor option for up to $15 million.

The initial $5 million equity investment bought 687,758 shares at $7.27 each. Those shares equal approximately 0.75% of the 91.873 million shares outstanding at September 30; that dated denominator is illustrative because it precedes the November issuance and any intervening changes. Future equity issuance depends on the applicable conditions and future pricing.

The loans mature in November 2033 and carry a floating rate with a 6.95% floor and an 8.95% cap. For the first three years after each advance, half the interest is added to principal, increasing the eventual repayment balance. Starting in October 2028, a separate royalty participation applies to specified U.S. sales and is capped at 20% of funded principal, subject to the agreement’s terms. With the initial $50 million advance alone, the cap is $10 million; additional advances would increase it. Repaying the loan alone does not terminate that obligation; if it remains outstanding at the November 2036 outside date, the unpaid amount up to the applicable cap is due.

Kura says its September 30 cash and investments would fund its current plan into 2028. Its expectation of funding beyond initial KOMET-017 results also incorporates $180 million of anticipated Kyowa Kirin milestone payments and conditional Oberland financing. Those future resources should not be treated as cash already on hand.

The next source of growth

Kura is studying ziftomenib-based combinations in newly diagnosed NPM1-mutated AML through the Phase 3 KOMET-017 program. Moving into earlier treatment could expand the eligible patient population, but it requires evidence from the ongoing studies and subsequent regulatory review. Kura expects initial topline results in 2028.

The company is also preparing a roughly 40-patient single-arm registrational study of darlifarnib in HRAS-mutated salivary gland cancer, with initiation targeted for the first half of 2027. That offers a separate development path, while adding to the work funded by the current balance sheet.

Until the frontline data arrive, the most useful commercial evidence will be whether more treatment centers prescribe KOMZIFTI and whether repeat prescriptions continue to grow. Sustained sales growth would improve the contribution from the current indication, while the cost of development, shared commercialization economics and financing obligations determine how much of that contribution Kura retains.